GS-3242 GS-3242 PHASE1
Drug Profile
ModalitySmall molecule
RouteSC
Therapy AreaInfectious Disease
Peak Sales Est$3000M
Formulations[]
Companies
GILD (ORIGINATOR)100%
Mechanism: Long-acting integrase inhibitor
Expert: Long-acting integrase strand transfer inhibitor (INSTI) optimized for co-administration with lenacapavir as a twice-yearly complete injectable HIV regimen.
Everyday: A long-acting drug designed to be injected twice yearly alongside lenacapavir for HIV treatment.
Targets: ["HIV INTEGRASE"]
Programs (1)
IndicationStageKey StudyRegional Status
HIV-1 treatmentPHASE1Phase 1
Upcoming Catalysts (1)
GS-3242 - HIV Treatment - Ph1 Data (Virology Conference) 2026
Data from Supabase · Updated 2026-03-24